Click HERE for An Update On Surface Pharmaceuticals

February 4, 2021
Surface Ophthalmics Announces First Patient Dosed in Phase II Trial for SURF-200 for Acute Dry Eye
Read full article >>

January 27, 2021
Surface Ophthalmics Announces First Patient Dosed in Landmark Head-to-Head Phase II Trial for SURF-100 for Chronic Dry Eye Disease
Read full article >>

January 21, 2021
Surface Ophthalmics Announces Positive Top-Line Results from Phase II Trial for SURF-201 (Betamethasone 0.2% in Klarity® vehicle) for the Treatment of Post-Cataract Surgery Pain and Inflammation
Read full article >>

January 07, 2021
Surface Ophthalmics Previews Important Clinical Progress in 2021
Read full article >>

October 01, 2020
Surface Pharmaceuticals Further Strengthens Board of Directors as Clinical Programs Advance
Read full article >>

September 03, 2020
Surface Pharmaceuticals Strengthens Leadership Team as Clinical Programs Advance in Eye Care
Read full article >>

May 15, 2018
Investment will enable Surface to fund its development programs focused on FDA approval of its ocular disease drug candidates
Read full article >>

October 24, 2017
Experienced Team to Advance Ocular Surface Disease Care by Seeking FDA-Approval for Three Branded Drug Programs Through FDA’s 505(b)(2) Development Pathway
Read full article >>